Psychopharmakologische Behandlung von Depressionen im Kindes- und Jugendalter
Entwicklungen und Standards seit der «Black Box» Warnung
Abstract
Die psychopharmakologische Behandlung kann – je nach Schweregrad- eine wichtige Option in der Therapie depressiver Erkrankungen bei Kindern und Jugendlichen darstellen. Diese Überblicksarbeit gibt klinische Behandlungsempfehlungen mit einem Fokus auf den Umgang mit Suizidalität und therapieresistenten Patienten. Die Studienlage zur medikamentösen Therapie der depressiven Erkrankung im Kindes- und Jugendalter hat sich seit den Warnungen der amerikanischen Zulassungsbehörde zum Auftreten von Suizidalität unter Therapie mit Selektiven Serotonin Wiederaufnahmehemmern (SSRIs) deutlich verbessert. In der Versorgung von depressiven Kindern und Jugendlichen ist in den letzten Jahren in Deutschland ein Trend hin zu einer evidenzbasierten psychopharmakologischen Therapie zu erkennen.
Depending on symptom severity, psychopharmacological treatment can be a valuable option in the treatment of depressive disorders in childhood and adolescence. This review provides recommendations for clinical treatment, focusing on suicidality and treatment-resistant patients. The quality of studies regarding the psychopharmacological therapy of depressive disorders in childhood and adolescence has improved since the «black box» warning of the FDA concerning the occurrence of suicidality under treatment with selective serotonin reuptake inhibitors (SSRIs). In Germany, there is proof for a trend toward a more evidence-based psychopharmacological treatment approach within recent years.
Literatur
2009). Treatment of selective serotonin reuptake inhibitor-resistant depression in adolescents: Predictors and moderators of treatment response. Journal of the American Academy of Child and Adolescent Psychiatry, 48, 330–339.
(2007). Practice parameters for the assessment and treatment of children and adolescents with depressive disorders. Journal of the American Academy of Child and Adolescent Psychiatry, 46, 1503–1526.
. (2004). Antidepressants and pediatric depression – the risk of doing nothing. New England Journal of Medicine, 351, 1598–1601.
(2009a). Predictors of spontaneous and systematically assessed suicidal adverse events in the treatment of SSRI-resistant depression in adolescents (TORDIA) study. American Journal of Psychiatry, 166, 418–426.
(2008). Switching to another SSRI or to venlafaxine with or without cognitive behavioural therapy for adolescents with SSRI-resistant depression: The TORDIA randomized controlled trial. Journal of the American Medical Association, 299, 901–913.
(2009b). The Treatment of Adolescent Suicide Attempters study (TASA): Predictors of suicidal events in an open treatment trial. Journal of the American Academy of Child and Adolescent Psychiatry, 48, 987–996.
(2004). Clinical response and risk for reported suicidal ideation and suicide attempts in pediatric antidepressant treatment. Journal of the American Medical Association, 297, 1683–1696.
(2007). Prevalence and Psychological correlates of occasional and repetitive Deliberate Self-Harm in adolescents. Archives of Pediatrics and Adolescent Health, 161, 641–649.
(2007). Leitlinien zur Diagnostik und Therapie von psychischen Störungen im Säuglings-, Kindes- und Jugendalter. Köln: Dt. Ärzteverlag.
(2006). Suicidal behaviour in youths with depression treated with new-generation antidepressants: Meta-analysis. The British Journal of Psychiatry, 189, 393–398.
(2010). Treatment of Resistant Depression in Adolescents (TORDIA): Week 24 outcomes. American Journal of Psychiatry, 167, 782–791.
(2009). Escitalporam in the treatment of Adolescent Depression: A randomized placebo-controlled multisite trial. Journal of the American Academy of Child and Adolescent Psychiatry, 48, 721–729.
(2004). Depressionsbehandlung mit SSRI in der Kinder- und Jugendpsychiatrie Ein Forschungs- oder ein Informationsdebakel? Nervenheilkunde, 23, 61–67.
(2004). Zum Einsatz von Serotoninwiederaufnahmehemmern (SSRI) bei depressiven Kindern und Jugendlichen. Zeitschrift für Kinder- und Jugendpsychiatrie und Psychotherapie, 32, 74–75.
(2006). Antidepressant use in children and adolescents in Germany. Journal of Child and Adolescent Psychopharmacology, 16, 197–206.
(2007). Revisions to product labeling. Download unter www.fda.gov/downloads/Drugs/DrugSafety/InformationbyDrugClass/UCM173233.pdf
. (2012a). Suicidal thoughts and behaviour with antidepressant treatment. Archives of General Psychiatry. doi 10.1001/ archgenpsychiatry.2011.2048
(2007). Early evidence on the effects of regulators suicidality warnings on SSRI prescriptions and suicide in children and adolescents. American Journal of Psychiatry, 164, 1356–1363.
(2012b). Benefits from antidepressants: Synthesis of 6-week patient-level outcomes from double-blind placebo-controlled randomized trials of Fluoxetine and Venlafaxine. Archives of General Psychiatry. Epub ahead of print. doi: 10.1001/ archpenpsychiatry.2011-2049.
(2007). Selective serotonin reuptake inhibitors (SSRIs) and routine specialist care with and without cognitive behavior therapy in adolescents with major depression: Randomised controlled trial. British Medical Journal, 335, 142–150.
(2006). Suicidality in pediatric patients treated with antidepressant drugs. Archives of General Psychiatry, 63, 332–339.
(2012). Outpatient treatment in German adolescents with depression: An analysis of nationwide health insurance data. Pharmacoepidemiology Drug Safety, 21, 972–979.
(2012). Antidepressiva. In , Handbuch der psychiatrischen Pharmakotherapie (2. Auflage, S. 589–629). Berlin, Heidelberg: Springer-Verlag.
(2012). Adolescents’ self-reported suicide attempts, self-harm thoughts and their correlates across 17 European countries. Journal of Child Psychology and Psychiatry, 53, 381–389.
(2012). Therapeutic drug monitoring of children and adolescents using fluoxetine. Pharmacopsychiatry, 45, 72–76.
(2009). Psychotropic medication in children and adolescents in Germany: Prevalence, indications, and psychopathological patterns. Journal of Child and Adolescent Psychopharmacology, 19, 765–770.
(2007). Decline in treatment of pediatric depression after FDA advisory on risk of suicidality with SSRIs. American Journal of Psychiatry, 164, 884–891.
(2011). Incremental cost-effectiveness of combined therapy vs medication only for youth with selective serotonin reuptake inhibitor-resistant depression: Treatment of SSRI-resistant depression in adolescents trial findings. Archives of General Psychiatry, 68, 253–262.
(2011). Treatment-resistant depression in adolescents: Review and updates on clinical management. Depression Anxiety, 28, 946–954.
(2008). Frequency of provider contact after FDA advisory on risk of pediatric suicidality with SSRIs. American Journal of Psychiatry, 165, 42–50.
(2005). Depression in children and young people. Download unter www.nice.org.uk/CG28
. (2007). Impact of publicity concerning pediatric suicidality data on physician practice patterns in the United States. Archives of General Psychiatry, 64, 466–472.
(2008). Effects of food and drug administration warnings on antidepressant use in a nationals sample. Archives of General Psychiatry, 65, 94–101.
(2003). Relationship between antidepressant medication treatment and suicide in adolescents. Archives of General Psychiatry, 60, 978–982.
(2009). An international comparison of adolescent non-suicidal self-injury (NSSI) and suicide attempts: Germany and the USA. Psychological Medicine, 39, 1549–1558.
(2006). Treatment-emergent adverse events from selective Serotonin reuptake inhibitors by age group: Children versus adolescents. Journal of Child and Adolescent Psychopharmacology, 16, 159–169.
(2000). Social skills deficits associated with depression. Clinical Psychology Review, 20, 379–403.
(2011). Long-term outcome of adolescent depression initially resistant to selective serotonin reuptake inhibitor treatment: A follow-up study of the TORDIA sample. Journal of Clinical Psychiatry, 72, 388–396.
(2007). A randomized, double-blind, pacebo-controlled study of citalopram in adolescents with major depressive disorder. Journal of Clinical Psychopharmacology, 26, 311–315.
(2006). A double-blind, randomized, placebo-controlled trial of escitalopram in the treatment of pediatric depression. Journal of the American Academy of Child and Adolescent Psychiatry, 45, 280–288.
(2004). A randomized, placebo-controlled trial of citalopram for the treatment of major depression in children and adolescents. American Journal of Psychiatry, 161, 1079–1083.
(2004). Selective Serotonin Reuptake Inhibitors in childhood depression: Systematic review of published versus unpublished data. The Lancet, 363, 1341–1345.
(2010). Escitalopram in the treatment of major depressive disorder in adolescent patients. Pediatric Drugs, 12, 155–163.
(